Humacyte is trading 7.27% up now at $0.59 after investors weighed positive Phase 3 dialysis results and plans to file a supplemental biologics license application with the FDA during the second half of 2026.
- Q2 commercial sales totaled $0.4 million, while revenue and EPS missed expectations.
- The misses contributed to the prior session’s decline.
- The rebound appears tied to renewed focus on the dialysis opportunity and potential regulatory milestones, rather than broad market strength.